Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade
Naoki Hama, Takuto Kobayashi, Nanumi Han, Fumihito Kitagawa, Nabeel Kajihara, Ryo Otsuka, Haruka Wada, Heekyung Lee, Hwanseok Rhee, Yoshinori Hasegawa, Hideo Yagita∥, Muhammad Baghdadi, Ken‐ichiro Seino
Abstract
T cells and M1-biased macrophages) and molecular (including various cytokines and chemokines) effectors at the tumor microenvironment. Then, a neutralizing antibody against IL-34 improved the therapeutic effects of the immune checkpoint blockade in combinatorial therapeutic models, including a patient-derived xenograft model. Collectively, we revealed that tumor-derived IL-34 inhibits the efficacy of immune checkpoint blockade and proposed the utility of IL-34 blockade as a new strategy for cancer therapy.
Topics & Concepts
BlockadeImmune checkpointCancer researchImmune systemTumor microenvironmentChemokineMonocyteImmunologyCD8BiologyImmunotherapyReceptorBiochemistryImmune cells in cancerImmune Cell Function and InteractionImmunotherapy and Immune Responses